| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $395,567 | 22 | 100 |
| Adler Eric | Chief Medical Officer | 0 | $0 | 4 | $40,404 | $-40,404 |
| Robertson Jenny | Chief Legal Officer | 0 | $0 | 4 | $40,594 | $-40,594 |
| See Tai Sandi | Chief Development Officer | 0 | $0 | 4 | $41,146 | $-41,146 |
| Otero Jose Manuel | Chief Technical Officer | 0 | $0 | 5 | $64,868 | $-64,868 |
| Townsend Richard Nolan | Chief Executive Officer | 0 | $0 | 5 | $208,554 | $-208,554 |
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Over the last 12 months, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $0 and sold $395,567 worth of Lexeo Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $5.05M and sold $287,357 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $104,852 was made by CHOLMONDELEY PAULA H (director) on 2024‑11‑25.
| 2026-02-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 10,173 0.0141% | $6.38 | $64,924 | +7.21% | |
| 2026-02-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 3,016 0.0042% | $6.40 | $19,294 | +7.21% | |
| 2025-11-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 1,127 0.0034% | $9.27 | $10,447 | -14.92% | |
| 2025-11-18 | Sale | Adler Eric | Chief Medical Officer | 615 0.0019% | $9.27 | $5,701 | -14.92% | |
| 2025-11-18 | Sale | Robertson Jenny | Chief Legal Officer | 549 0.0017% | $9.27 | $5,089 | -14.92% | |
| 2025-11-18 | Sale | See Tai Sandi | Chief Development Officer | 386 0.0012% | $9.27 | $3,578 | -14.92% | |
| 2025-11-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 721 0.0022% | $9.27 | $6,684 | -14.92% | |
| 2025-10-17 | Sale | Townsend Richard Nolan | Chief Executive Officer | 13,133 0.0369% | $8.94 | $117,436 | -6.16% | |
| 2025-10-17 | Sale | Adler Eric | Chief Medical Officer | 3,382 0.0095% | $8.94 | $30,242 | -6.16% | |
| 2025-10-17 | Sale | Robertson Jenny | Chief Legal Officer | 3,526 0.0099% | $8.94 | $31,530 | -6.16% | |
| 2025-10-17 | Sale | See Tai Sandi | Chief Development Officer | 3,888 0.0109% | $8.94 | $34,767 | -6.16% | |
| 2025-10-17 | Sale | Otero Jose Manuel | Chief Technical Officer | 2,115 0.0059% | $8.94 | $18,913 | -6.16% | |
| 2025-08-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 2,735 0.0078% | $4.67 | $12,767 | +57.73% | |
| 2025-08-18 | Sale | Adler Eric | Chief Medical Officer | 608 0.0017% | $4.67 | $2,838 | +57.73% | |
| 2025-08-18 | Sale | Otero Jose Manuel | Chief Technical Officer | 721 0.0041% | $9.27 | $6,684 | +57.73% | |
| 2025-08-18 | Sale | Robertson Jenny | Chief Legal Officer | 542 0.0015% | $4.67 | $2,530 | +57.73% | |
| 2025-08-18 | Sale | Otero Jose Manuel | Chief Technical Officer | 2,848 0.0081% | $4.67 | $13,294 | +57.73% | |
| 2025-08-18 | Sale | See Tai Sandi | Chief Development Officer | 382 0.0011% | $4.67 | $1,783 | +57.73% | |
| 2025-05-16 | Sale | Townsend Richard Nolan | Chief Executive Officer | 1,074 0.0028% | $2.77 | $2,979 | +105.56% | |
| 2025-05-16 | Sale | Adler Eric | Chief Medical Officer | 585 0.0015% | $2.77 | $1,623 | +105.56% |
| Townsend Richard Nolan | Chief Executive Officer | 392483 0.5377% | $2.69M | 0 | 10 | |
| Otero Jose Manuel | Chief Operating Officer | 125460 0.1719% | $859,401.00 | 0 | 5 | |
| Adler Eric | Chief Medical Officer | 72646 0.0995% | $497,625.10 | 0 | 5 | |
| Robertson Jenny | Chief Legal Officer | 68381 0.0937% | $468,409.85 | 0 | 5 | |
| See Tai Sandi | Chief Development Officer | 65476 0.0897% | $448,510.60 | 0 | 5 | |
| Longitude Capital Partners IV, LLC | 10 percent owner | 2567100 3.5172% | $17.58M | 1 | 0 | +25.53% |
| Omega Fund VI, L.P. | 10 percent owner | 2157623 2.9562% | $14.78M | 1 | 0 | +25.53% |
| CHOLMONDELEY PAULA H | director | 30627 0.042% | $209,794.95 | 1 | 0 | <0.0001% |
$3,611,891 | 113 | 13.40% | $508.98M | |
$1,323,997 | 34 | 0.21% | $491.95M | |
$63,049,419 | 31 | 2.87% | $504.61M | |
$74,231,875 | 30 | 40.62% | $481.62M | |
$22,017,898 | 24 | 39.19% | $447.15M | |
$4,306,464 | 21 | 37.34% | $450.53M | |
$112,238,340 | 19 | 39.16% | $516.26M | |
$104,137,421 | 15 | 21.28% | $478.79M | |
$7,254,955 | 14 | 20.70% | $524.03M | |
$15,149,818 | 12 | 2.98% | $466.36M | |
$57,263,116 | 11 | -8.37% | $516.88M | |
$79,246,559 | 5 | -27.73% | $525.89M | |
$4,745,999 | 5 | -4.91% | $453.2M | |
$144,224 | 4 | 21.31% | $505.55M | |
$58,352 | 4 | -43.78% | $523.17M | |
Lexeo Therapeutics, Inc. Common Stock (LXEO) | $10,104,842 | 3 | 5.45% | $499.96M |
$184,294 | 3 | -10.64% | $460.17M | |
$2,857,000 | 2 | -5.23% | $509.13M | |
$300,016 | 1 | -50.33% | $477.14M |
| Increased Positions | 106 | +123.26% | 34M | +69.01% |
| Decreased Positions | 37 | -43.02% | 7M | -14.17% |
| New Positions | 46 | New | 21M | New |
| Sold Out Positions | 11 | Sold Out | 1M | Sold Out |
| Total Postitions | 155 | +80.23% | 76M | +54.83% |
| Janus Henderson Group Plc | $58,674.00 | 8.36% | 6.11M | +2M | +65.71% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $42,522.00 | 6.06% | 4.42M | 0 | 0% | 2025-09-30 |
| Balyasny Asset Management L.P. | $37,612.00 | 5.36% | 3.91M | -95,349 | -2.38% | 2025-09-30 |
| Affinity Asset Advisors, Llc | $37,196.00 | 5.3% | 3.87M | +281,172 | +7.83% | 2025-09-30 |
| Citadel Advisors Llc | $35,740.00 | 5.1% | 3.72M | +111,076 | +3.08% | 2025-09-30 |
| Vestal Point Capital, Lp | $31,233.00 | 4.45% | 3.25M | +21,839 | +0.68% | 2025-09-30 |
| Woodline Partners Lp | $24,718.00 | 3.52% | 2.57M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $22,234.00 | 3.17% | 2.31M | -522,650 | -18.43% | 2025-09-30 |
| Vanguard Group Inc | $21,395.00 | 3.05% | 2.23M | +223,424 | +11.15% | 2025-09-30 |
| Blackrock, Inc. | $20,864.00 | 2.97% | 2.17M | +343,128 | +18.77% | 2025-09-30 |